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ABSTRACT (~150 words) 
The bacterial enzymes DsbA and DsbB together mediate introduction of stabilizing disulfide bonds 
into bacterial virulence factors, and may be novel targets for antivirulence drugs. Here, we report the 
discovery of synthetic analogues of ubiquinone (dimedone derivatives) that inhibit disulfide bond 
formation (IC50 ~1 μM) catalysed by E. coli DsbA:DsbB, a dual enzyme redox system. The inhibition 
mechanism involves covalent modification of a free cysteine in each enzyme, revealed by mass spectra 
for each complex and supported by NMR spectra for reduced E. coli DsbA. A vinologous anhydride in 
each inhibitor is cleaved by the thiol, which becomes covalently modified to a thioamide by a 
propionyl substituent. Inhibition of bacterial DsbA:DsbB catalyzed disulfide bond formation, together 
with its importance in regulating virulence, supports this enzyme system as a viable target for 
antimicrobial agents. Inhibiting bacterial virulence rather than growth may slow development of 
resistance to antibacterial drugs.  
 
I think TOC should be modified to show the 
key finding, that the thiol attacks the carbonyl. Maybe just show an arrow from the SH to the carbonyl. 
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Introduction 
The development of bacterial resistance to antibiotics is a global concern, and has been described as a 
looming public health crisis (1, 2). Multi-drug resistant strains of Gram-negative bacteria, such as 
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa, as well as Gram-positive 
bacteria such as Staphylococcus aureus, have proven to be difficult to treat with current antibiotics (3). 
New approaches involving different mechanisms of drug action, that can bypass bacterial resistance 
mechanisms used against existing drugs, are needed to combat bacterial infections. One strategy is to 
target bacterial pathogenicity and virulence, rather than interfering with bacterial survival. This strategy 
may reduce the selective pressure for resistance development (4, 5).  
 
Many bacterial virulence factors require structural bracing by disulfide bonds for their stability and 
function (6, 7). Disulfide bonds in bacteria are introduced in proteins by the DiSulfide Bond (DSB) 
system that acts on a wide range of virulence factors including protein toxins, adhesins, and secretion 
systems (7, 8). 
 
The archetypal E. coli K-12 DSB system (REFERENCE showing this nomenclature which wont be 
understood by anyone including me) comprises the periplasmic oxidoreductase E. coli DsbA (EcDsbA) 
and the membrane-bound protein E. coli DsbB (EcDsbB). EcDsbA is highly oxidizing, with a redox 
potential of –120 mV. The active-site sequence Cys30-Pro-His-Cys33 has unusual properties. First, 
Cys30 has a highly acidic pKa of 3–3.5. Second, the reduced dithiol form is more stable than the 
oxidized disulfide form of the enzyme (8, 9). EcDsbB is a membrane protein with two reactive cysteine 
pairs (Cys41-Cys44 and Cys104-Cys130) located on its two periplasmic loops. These act in concert 
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with ubiquinone (UQ8) or menaquinone (MK8) to maintain EcDsbA in the active oxidized form (10-
13).  
 
The DSB system has been described as a master regulator of virulence in bacteria (7). Deletion or 
mutation results in pleiotropic effects and attenuated virulence with no effect on bacterial growth (7, 8). 
Perhaps the most compelling evidence for its importance in virulence comes from studies on 
Burkholderia pseudomallei, a Gram-negative bacterium that is highly pathogenic, naturally drug 
resistant and for which infections have a high mortality rate. All mice infected with wild type B. 
pseudomallei died, whereas all mice infected with the strain missing DsbA (ΔdsbA) survived even after 
42 days, with little or no phenotypic evidence of infection (14). Similarly, deletion of dsbA in 
Haemophilus influenzae had significantly lower bacteremia counts in animal models (15). DSB 
proteins are therefore implicated as possible targets for development of antivirulence drugs.  
 
We set out to discover novel inhibitors of the membrane protein EcDsbB. During NMR screening of 
membrane proteins, other had identified several small molecules from a drug-like fragment library that 
bound very weakly to EcDsbB (16). We selected one of these compounds, shown to compete with 
ubiquinone for binding to EcDsbB, as a starting point for inhibitor development. Here, we report our 
systematically explored structure-activity relationship (SAR) studies, focusing on a 5,5-dimethyl-1,3-
cyclohexanedione (dimedone) scaffold. 
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Results and Discussion 
To assess DSB inhibition, a rapid screening assay was installed to monitor effects on the formation of 
disulfide bonds in a synthetic peptide substrate. The redox sensitive fluorescence substrate allows 
measurement in real-time of the oxidoreductase activity of the DSB system. The assay has been used 
previously to characterize the oxidase activity of several DSB proteins (17, 18). Here, it was used as a 
screening tool to rapidly identify potential inhibitors. However the assay does not discriminate between 
inhibitors of EcDsbA or EcDsbB. Representative data from the assay are shown in Figure 1A, with 
decreasing fluorescence correlating with increasing inhibitor concentration, and indicating inhibition of 
DSB activity. A plot of the initial rates of reaction versus the log of the concentration of inhibitor gave 
a concentration-response curve for calculating inhibitor potency (Figure 1B) 
 
Inhibitor design initially focused on compound 1 (Figure 1D), reported to compete weakly with 
ubiquinone at its binding site in EcDsbB (16). To our knowledge no follow-up structure activity 
relationships have been reported. Its reported potency (IC50 100 µM) referred to inhibition of 
ubiquinone reduction (19). In the peptide oxidation assay used here, 1 proved to be an extremely poor 
inhibitor (IC50 2-5 mM). The assays differed in a number of respects. First, the peptide oxidation assay 
utilized a membrane preparation of EcDsbB and either the lipid components or the different detergents 
used may have interfered with the inhibitor accessing its site of action. Moreover, the EcDsbB we used 
was likely to be bound to ubiquinone, which the inhibitor may have had to dislodge in order to inhibit 
activity. This may not have been the case in the previously study (19), where the cyanoborohydride 
used to attach EcDsbB to nanodiscs for assays may have reduced ubiquinone to ubiquinol. 
Nevertheless, some inhibition was detectable in our assay for compound 1 (see Figure 1), so we 
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decided to derive other potential inhibitors from it.  A summary of the SAR data is given in Table 1 for 
a range of small organic molecules derived from 1.  
 
We focused on the core 5,5-dimethyl-1,3-cyclohexanedione (dimedone) scaffold. To probe the enzyme 
active site further, we stripped off the 2-propionoyl, 4-phenyl and the two 5-methyl groups from the 
dimedone ring in 1 and added a phenylbutanoyl chain to create the novel phenylbutanoate compound 2. 
This structure mimics to some extent the endogenous ubiquinone cofactor of EcDsbB, with an aliphatic 
tail and bulky headgroup (Figure 1 C) and was a much more potent inhibitor (IC50 24 µM) than 1. 
When the 5,5-dimethyl substituents were reinserted (3) there was little improvement (IC50 19 µM). 
Incorporating the ester onto the dimedone scaffold (at the C2 position via lactone formation) 
inactivated the compound (4). To probe the binding space further, one of the 5-methyl groups of 3 was 
replaced by a phenyl group and this improved inhibitor potency 2-fold (5, IC50 9.5µM).  
 
Next, we investigated whether replacing the 4-phenylbutanoate with a simple propionate (6) would 
retain activity. This modification slightly improved potency compared to 5. We therefore concluded 
that the bulky chain extending from the ester group was not required for potency, however the ester 
moiety was essential for inhibition as its removal in 7 abolished activity.  To further probe the space 
around the phenyl moiety, a meta-chlorine substituent was added to the phenyl group of 6, giving 8 and 
a significant improvement in inhibitor potency (IC50 1.3 µM).  
 
Using compound 8 as a core structure, we then designed derivatives to probe the ester functionality 
further, but these gave little or no improvement in IC50 (data not shown). Replacing the propionyl group 
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with a chlorobutanoyl (9) did not improve inhibitory activity. Removing the chlorine and maintaining a 
four-carbon chain also did not improve inhibitory activity (IC50 2.6 µM vs 1.3 µM for 10 and 8, 
respectively) and replacing the propionyl with a bulky pivaloyl group (11) decreased potency by >20-
fold (IC50 43 µM). 
 
The importance of the ester group was further assessed by modifying it into an ether linkage or 
changing the ketone group into a ketoxime (12 and 13). However both changes rendered the molecule 
inactive. Returning to the scaffold of 9, replacing the C5-methyl group with a benzyl substituent (14) 
almost doubled the IC50 to 2.2µM (15 vs 9). An additional chlorine, ortho- or para- in the phenyl ring 
(15 and 16 respectively), did not improve activity significantly. Substitution of the m-chlorine with a 
phenyl ring (17) increased IC50 >2-fold (17 vs 8). Replacing m-chlorine with other halogens showed 
that fluorine (18) reduced the inhibitory activity by 3-fold giving IC50 3.6 µM (18 vs 8). However, the 
larger bromine (19) improved the inhibitory activity a little (IC50 1.1 µM). Compound 19 was the most 
active inhibitor from this study. 
 
To investigate interactions formed between the inhibitor and protein, mass spectrometry techniques 
were applied. First, mass spectra of the purified EcDsbB (solubilized in detergent micelles) were 
obtained following nanoflow electrospray (nanoES) using a gas phase activation strategy described 
previously (20). Two isoforms of the protein were detected (Figure 2A), the major form at m/e 21,200 
KDa. In the presence of three different inhibitors (9, 19 and 19  should this be 8, 18, 19 as below?) at 
varying concentrations, successive binding of 56 Da entities to DsbB was observed. These entities were 
not detached upon higher activation conditions, implying a covalent interaction.  
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To further demonstrate covalent binding, an equimolar mixture of EcDsbB and 8 was subjected to 
denaturing LC-MS/MS. Four residues modified by a 56 Da entity were detected: three of these were 
lysines (at position 167, 169 and 170 in the C-terminal peptide 167KAKKRDLF174), and the fourth was a 
cysteine at position 130 in the fragment 125VASGDCAERQW135 (Figure 2B). To gain insight into the 
nature of the covalent modification, solutions of 8, 18 and 19 were subjected to electrospray by direct 
infusion to test the stability of the inhibitors upon nanoES in the gas phase. All intact protonated 
inhibitors were detected, the major forms being with one DMSO adduct. However, a fragment ion 
resulting in the neutral loss of 56 Da was also present. When isolating the parent ion of the intact 
inhibitor, the major peak corresponded to the neutral loss of 56 Da even at the minimum collision 
energy. These results demonstrate that the inhibitors are not stable upon ESI or in the gas phase, and 
have a tendency to fragment losing a propionate.  
Addition of the propionate to the C-terminal Lys residues of EcDsbB is unlikely to affect the activity of 
the protein. However, covalent attachment of the propionate to EcDsbB Cys130 will adversely affect 
the ability of EcDsbB to re-oxidize DsbA, because Cys130 is essential for this process (11). Although 
Cys130 is relatively buried in the structures of the EcDsbA-EcDsbB complex, there is a degree of 
flexibility in the region of Cys130 (21, 22) that may expose this residue to the solvent, allowing 
covalent attachment of the compounds.  
 
Since the peptide oxidation assay does not discriminate between inhibition of EcDsbA and EcDsbB, we 
also investigated the effect of the compounds on EcDsbA by nanoES. Mass spectra showed that Cys33 
in the fragment [27SFFCPHCY34] was also covalently modified by a 56 Da adduct (data not shown). 
Further investigation of the binding of inhibitors to EcDsbA was undertaken using 1H,15N-HSQC 
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NMR. Compound 19 was added to a sample of both oxidized and reduced forms of 15N-labeled 
EcDsbA causing localized perturbations around the active site (Figure 2C).  Subsequently, each 
complex was re-purified by size exclusion chromatography (SEC) and a 1H,15N-HSQC re-acquired. In 
the case of oxidized EcDsbA, SEC removed compound 19 and the HSQC spectrum was consistent with 
apo-oxidized EcDsbA. In the case of reduced EcDsbA, SEC had no effect on the HSQC spectrum 
obtained for the complex. These results suggest that 19 forms a covalent complex with reduced 
EcDsbA, but binds non-covalently to oxidized EcDsbA adjacent to the active site, supporting the 
results obtained from mass spectrometry where covalent attachment of the adduct to only one Cys in 
each of the EcDsbA and EcDsbB enzymes suggests a degree of specificity and the formation of a stable 
enzyme-inhibitor complex before covalent attachment occurs (Figure 3A). Compounds 1-19 are more 
correctly described as “vinylogous anhydrides” than esters and covalently modify the nucleophilic side 
chains of cysteine and lysine by efficiently transferring the propionyl group, thus giving rise to the 56 
Da adducts of the protein observed in the mass spectra (Figure 3B).  Insert reference: J. Phys. Org. 
Chem. 2008, 21 1022–1028 DOI 10.1002/poc.1435 The alternative pathway of Michael addition 
followed by elimination of propionate (Figure 3B) was not observed by mass spectroscopy, consistent 
with calculations that predict this pathway to be of minor significance. Same Reference 
 
Our initial starting point was a compound (1) identified to weakly bind and inhibit the activity of the 
membrane protein EcDsbB. We generated a library of analogues, including compounds that over 1,000 
times more potent than 1 in inhibiting DSB-catalysed formation of disulfide bonds, the most potent 
inhibitor 19 binding covalently to a single cysteine in EcDsbB and EcDsbA. Both enzymes are 
candidate targets for the development of new antimicrobials. In summary, the findings validate the 
DSB system as a potential new target for small molecule inhibitors. Since this system is important for 
bacterial virulence, new inhibitors developed for the DSB system may be antivirulence drugs, and the 
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dimedone inhibitors have been instrumental tools here to validate the DSB system as a viable target for 
small molecule inhibitors. Further efforts to examine more druggable compounds against this target 
system may lead to a new class of antivirulence drugs to thwart current bacterial resistance 
mechanisms.  
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METHODS 
Protein purification 
EcDsbA in a pMCSG7 vector was expressed as a cytoplasmic protein with an N-terminal His6-tag and 
a TEV protease-recognition site. The plasmid was inserted into BL21(DE3)pLysS cells and 
transformed cells were used for protein expression by auto-induction with ampicillin. TALON resin 
(Clontech, Australia) was pre-equilibrated with buffer in a gravity column and supernatant passed 
through resin to bind His6-tagged EcDsbA. The His6-tag was removed by TEV protease digest. Cleaved 
protein was collected by running sample over pre-equilibrated TALON and collecting the flow-
through. Protein was further purified by running over a size-exclusion column (GE Superdex 75 16/60) 
and peak fractions pooled and assessed for purity by SDS-PAGE gel.  
 
The dsbB gene in a pQE-70 vector (JCB851) with a C-terminal His6-tag was obtained from our 
collaborators at Monash University and Professor James Bardwell (University of Michigan). EcDsbB 
contains the mutations Cys8Ala and Cys49Val to aid in purification. EcDsbB was expressed and 
purified as described previously (18) except for buffer, which was PBS. Membrane-bound EcDsbB was 
quantified using SDS-PAGE 12% gels, and used in the peptide oxidation assay. For mass spectrometry, 
EcDsbB was purified from the membrane by re-suspending membrane in PBS buffer and solubilized 
with detergent n-dodecyl-b-D-maltopyranoside (DDM) 1% w/v. Membrane debris was removed by 
ultracentrifugation at 38,000 rpm for 1 hr at 4°C. Supernatant was collected and PrepEase  (USB 
Corporation, Cleveland, OH) used to bind protein. Further purification was done using size-exclusion 
chromatography (Superose 6 10/300 GL) with PBS containing 0.03% w/v DDM. Fractions were 
monitored by SDS-PAGE gels to check purity.  
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Peptide oxidation assay 
The peptide substrate CQQGFDGTQNSCK with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA) chelate on the N-terminus and a methylcoumarin amide (MCA) group coupled to the ε-
amino group of the lysine was used. Lyophilized peptide (Anaspec, USA) was reconstituted in buffer 
(100mM imidazole, pH 6) at 2 mM concentration. Europium trifluoromethansulfonate (Sigma Aldrich, 
Australia) was added to the peptide solution at a molar ratio of 2:1 peptide to europium salt. The 
solution was left for 5 min at room temperature, then aliquoted into eppendorf tubes and immediately 
snap frozen in liquid nitrogen. 
 
Inhibitor screening was performed in 384-well white plates (Perkin Elmer, Australia). Protein was 
added to the final concentrations of 80 nM EcDsbA and 1.6 µM EcDsbB membrane solution, in 50 mM 
MES, 50 mM NaCl, 2 mM EDTA buffer, pH 5.5. Peptide substrate was added last to a final 
concentration of 8 µM in a total 50 µL volume. Assay was run on a Synergy H1 Multimode Plate 
Reader (Biotek, USA) with excitation 340 nm and emission 615nm, a delay of 100 m s before read and 
100 m s read time. Compounds were analysed in duplicates per plate, and tested at least three times on 
separate occasions. Data was plotted and analyzed using GraphPad Prism version 5.0 (GraphPad 
Software, Inc. USA). For calculating the IC50 values, the initial rates of the reaction were calculated 
over the linear portion of the curve (the first 10 or 20 min of each reaction) and normalized as a 
percentage relative to no inhibitor present. 
 
Synthesis of DsbB inhibitors 
A detailed description of the synthesis of compounds is given in the supporting information.  
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Mass spectrometry determination of EcDsbB 
Aliquots of EcDsbB were buffer exchanged against 200 mM ammonium acetate, 0.02% DDM, and 
EcDsbA against 200 mM ammonium acetate, using Micro Bio-spin 6 columns (BioRad). Inhibitor 
stock solutions were freshly prepared in DMSO at 10 mM concentration. Inhibitors were added to the 
protein at different concentrations, final DMSO was at 5 % to be consistent with the screening assays. 
For nanoflow electrospray mass spectrometry, spectra were acquired on a modified Q-ToF II mass 
spectrometer (Waters) (26) using in-house prepared gold-coated glass capillaries (27). To preserve non-
covalent interactions, the MS parameters were: capillary voltage 1.5 kV, cone voltage 80 V, extractor 5 
V, source backing pressure 6-8 mbar and collision cell pressure of 5 psi. Collision cell energy was 
between 60 and 200 V. Inhibitors were analysed in a Q Exactive hybrid quadrupole Orbitrap mass 
spectrometer (Thermo Scientific). The covalent binding sites were determined by denaturing LC-
MS/MS: EcDsbB or EcDsbA (either in ammonium acetate buffer or in 50 mM HEPES, 50 mM NaCl, 
pH 6.8, supplemented with 0.02 % DDM for EcDsbB), were mixed with inhibitor at equimolar ratios, 
the mixture was then ethanol precipitated and digested with chymotrypsin. Peptides were separated by 
reversed-phase nanoLC (DionexUltiMate 3000 RSLC nano System, Thermo Scientific) and directly 
analysed in a LTQ-Orbitrap XL hybrid mass spectrometer (Thermo Scientific). Potential binding sites 
were identified using the MassMatrix Database Search Engine (28, 29) then validated manually. Search 
parameters were as follows: Carbamidomethylation of cysteines and oxidation of methionine residues 
were allowed as variable modifications; the mass accuracy filter was 10 p.p.m. for precursor ions and 
0.8 Da for fragment ions; minimum pp and pp2 values were 5.0 and minimum pptag was 1.3. 
 
NMR spectroscopy 
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Interactions of PB-1-20 with oxidized and reduced EcDsbA were investigated by [15N,1H]-HSQC 
solution NMR spectroscopy. First, a [u-13C,15N]-labeled oxidized sample was prepared with protein 
concentration 100 µM and 50 mM HEPES (pH 6.8), 50 mM NaCl, 2% (v/v) d6-DMSO, 5% (v/v) D2O. 
The oxidized sample (protein concentration ~ 180 µM; 50 mM HEPES (pH 6.8), 50 mM NaCl) was 
further reduced by adding 100 fold excess of DTT, incubating for 1h at room temperature and then 
buffer exchanged using a PD10 column to remove DTT. A 200 mM stock solution of PB-1-20 was 
prepared in d6-DMSO and diluted to 20 mM and 10 mM.  Finally, for each state, three samples were 
prepared with EcDsbA: PB-1-20 ratio 1:0.5, 1:1 and 1:10 with a fixed concentration of 2% d6-DMSO, 
100 µM protein and 5% (v/v) D2O. All data was collected using approximately 160 µL sample volume 
in a 3 mm thick walled NMR tube. All NMR experiments were acquired on a 600 MHz spectrometer 
equipped with a CryoProbe at 298 K. The data were processed by Topspin 3.2 and analyzed by CARA. 
 
SUPPORTING INFORMATION: 
Synthetic and analytical methods for the compounds described here. 
This material is available free of charge via the Internet at http://pubs.acs.org. 
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Compound IC50 ± SEM (µM) n 
1 2000-5000 (100 # ) 3 
2 24 ± 1.6 3 
3 19 ± 1 4 
4 NA 3 
 5 9.4 ± 0.5 3 
6 6.9 ± 0.3 4 
7 NA 3 
8 1.3 ± 0.03 6 
 9 2.2 ± 0.08 4 
10 2.6 ± 0.1 3 
11 43 ± 3.1 3 
12  NA 3 
13 NA 3 
14  2.2 ± 0.08 4 
15 1.9 ± 0.05 4 
16 1.5 ± 0.09 3 
17 2.9 ± 0.1 3 
18 3.6 ± 0.2 3 
19 1.1 ± 0.02 6 
      NA = no activity  # value from Fruh et al (16) 
Table 1. Structure-activity relationship results of compounds screened in the peptide oxidation assay. 
All compounds were tested in duplicate on at least three separate occasions. IC50 values were calculated 
from the initial rates of the reaction and the means and standard errors of mean are reported.  
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Figure 1: Representative graphs of inhibitory activity using the peptide oxidation assay. (A) Raw data 
of fluorescence emission. As the concentration of inhibitor 19 increases, less fluorescence emission is 
observed. Data shown are from duplicates ± SD (B) A dose-response curve generated from the initial 
rates of the reaction, used to calculate the IC50 of 19. Data were from n=6 experiments and the mean ± 
SEM presented. (C) Structures of ubiquinone-8 and ubiquinone-1 (D) Structures of small molecule 
inhibitors used in this study.  
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Figure 2: Binding of inhibitors to EcDsbB. A) nanoES spectra of  the 13+ charge state of 75µM 
EcDsbB apo (lowest graph) or in the presence of 19 at different concentrations as indicated. Apo-
protein labeled in black, binding to the first, second and third inhibitor molecules are labeled (green, 
orange and purple, respectively). B) CID MS spectrum of the doubly charged peptide ion 
corresponding to the sequence [125VASGDCAERQW135] with the Cys at position 130 modified either 
by a carbamidomethyl group (top) or by the covalently bound inhibitor (bottom). Both sequences were 
verified by MS/MS. C) Chemical shift perturbations observed in the 15N-HSQC spectrum of (top) 
oxidised EcDsbA and (bottom) reduced EcDsbA upon addition of 19 (1 mM). In each case the 
perturbations are clustered around the active site of EcDsbA. In each case the largest perturbations are 
mapped onto the structure of EcDsbA (1FVK and 1A2L, respectively) with perturbed residues coloured 
red. 
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Figure 3: Schematic of EcDsbA:EcDsbB complex with the propionate adduct. A) Covalent attachment 
of the propionate to EcDsbB Cys130 prevents the protein from reoxidizing via a disulfide-dithiol 
exchange with the Cys41-Cys44 pair. At the same time, covalent attachment of the propionate to 
EcDsbA Cys33 prevents nucleophilic attack on the Cys30 and EcDsbA cannot be re-oxidized. B) The 
mechanism by which the inhibitors modify the enzymes is direct acylation (top) rather than the 
alternative Michael addition/elimination sequence (bottom). 
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